Large Panel of Validated Syngeneic Models Ready for Immunotherapeutic Evaluation
Immunotherapeutics fight cancer by taking advantage of a patient’s own immune system. Therefore, in vivo preclinical research into new therapies requires appropriate models with fully functional immunity.
Syngeneic tumor models (allografts derived from immortalized mouse cancer cell lines which originated from the same inbred strain of mice) provide a valuable system for assessing new single agent and combination immunotherapies within mice with fully competent immunity.
Well Validated Models: FACS, RNAseq, Checkpoint Inhibitor Benchmarking...
Our suite of syngeneic models includes nearly 20 cancer types, with over 30 models available or in development. Our models have full immune cell profiling via FACS, with RNAseq and treatment data also available.
We also have tumor tissue histology (H&E staining), and frozen and formalin-fixed, paraffin-embedded sygeneic tumor samples available as TMAs for ex vivo research uses as required.
Our standard syngeneic models are used to interrogate novel immune treatments with panels of our syngeneics utilized in checkpoint inhibitor evaluation, including anti-PD-1, PD-L1, and CTLA-4 antibodies, as well as combination therapies.
Syngeneic Panel Benchmarking with Anti-PD-1 Antibody
Through detailed RNAseq analysis, we have identified alternative gene splicing transcripts and gene fusions within our models, mutations useful for combination studies of targeted agents and immunotherapy, and can provide a set of biomarkers to predict response to different immunotherapies. We also provide baseline and post-treatment immune cell profiling.
Quick and Easy Model Selection
Selection of the appropriate syngeneic tumor models of interest is made easy by our curated online murine cancer model database MuBase®, and our powerful new search engine (which searches models from all our Oncology databases) OncoExpress™.
Advanced Models for Metastatic Modeling and Optical Imaging
Our advanced in vivo syngeneic tumor models include models of metastasis, including bioluminescent models, which allows clients to study clinically relevant metastatic invasion, metastatic lesions in secondary organs, and to evaluate their agents to target metastasis.
Introducing the First Large-Scale In Vivo Screening Platform for Immunotherapeutics
CrownBio has made the decision making process easy for the fast-track screening of your novel immunotherapeutics in MuScreen™, the first large-scale, staggered, in vivo screening platform for cancer immunotherapeutics. MuScreen can be used to rapidly focus immuno-oncology research efforts such as screening for efficacy, identifying PD markers, evaluating combination therapies, and qualifying drug resistance using our fixed Syngeneic Efficacy, PD, and Tumor Microarray panels.
Contact us today for more information on our syngeneic tumor models, or to enroll your compounds onto the next MuScreen.